Arrakis CEO cites ‘cul-de-sacs’ on street to RNA-intercepting most cancers medication
5 years in the past, a small startup led by means of biotech veteran Michael Gilman introduced growth in opposition to a most cancers gene that had bedeviled drug builders for 40